These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27443732)

  • 21. EU agencies accused of conflicts of interest.
    Butler D
    Nature; 2012 May; 485(7398):294-5. PubMed ID: 22596132
    [No Abstract]   [Full Text] [Related]  

  • 22. Improving uncertainty analysis in European Union risk assessment of chemicals.
    Verdonck FA; Souren A; van Asselt MB; Van Sprang PA; Vanrolleghem PA
    Integr Environ Assess Manag; 2007 Jul; 3(3):333-43. PubMed ID: 17695106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Masculine fertility threatened by the presence of endocrine disruptors in environment?].
    Dewalque L; Charlier C
    Rev Med Liege; 2012; 67(5-6):243-9. PubMed ID: 22891474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk assessment of 'endocrine substances': guidance on identifying endocrine disruptors.
    Lewis RW
    Toxicol Lett; 2013 Dec; 223(3):287-90. PubMed ID: 24036001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications of research on endocrine disruption for the environmental risk assessment, regulation and monitoring of chemicals in the European Union.
    Matthiessen P; Johnson I
    Environ Pollut; 2007 Mar; 146(1):9-18. PubMed ID: 16996184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing the aquatic toxicity assessment under REACH through an integrated testing strategy (ITS).
    Lombardo A; Roncaglioni A; Benfenati E; Nendza M; Segner H; Jeram S; Pauné E; Schüürmann G
    Environ Res; 2014 Nov; 135():156-64. PubMed ID: 25262089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Not Available].
    Nau JY
    Rev Med Suisse; 2019 Sep; 15(664):1726-1727. PubMed ID: 31553539
    [No Abstract]   [Full Text] [Related]  

  • 29. Biomarkers of endocrine disruption: cluster analysis of effects of plasticisers on Phase 1 and Phase 2 metabolism of steroids.
    Waring RH; Ramsden DB; Jarratt PD; Harris RM
    Int J Androl; 2012 Jun; 35(3):415-23. PubMed ID: 22372686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulations applicable to plant food supplements and related products in the European Union.
    Silano V; Coppens P; Larrañaga-Guetaria A; Minghetti P; Roth-Ehrang R
    Food Funct; 2011 Dec; 2(12):710-9. PubMed ID: 21997496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Problems in the system of state regulation of chemical safety].
    Novikov SM; Shashina TA; Khamidulina KhKh; Skvortsova NS; Ungurianu TN; Ivanova SV
    Gig Sanit; 2013; (4):19-24. PubMed ID: 24340595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. European activities in radiation protection in medicine.
    Simeonov G
    Radiat Prot Dosimetry; 2015 Jul; 165(1-4):34-8. PubMed ID: 25870434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Endocrine disrupters: Towards an unsatisfying regulation].
    Ravel C; Kah O
    Presse Med; 2018; 47(11-12 Pt 1):943-949. PubMed ID: 30217365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Composition, labelling, and safety of food supplements based on bee products in the legislative framework of the European Union - Croatian experiences.
    Vujić M; Pollak L
    Arh Hig Rada Toksikol; 2015 Dec; 66(4):243-9. PubMed ID: 26751855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of three approaches for regulatory decision making on pesticides with endocrine disrupting properties.
    Marx-Stoelting P; Niemann L; Ritz V; Ulbrich B; Gall A; Hirsch-Ernst KI; Pfeil R; Solecki R
    Regul Toxicol Pharmacol; 2014 Dec; 70(3):590-604. PubMed ID: 25239592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New EU regulations in endoscopy.
    Wächter M; Diekjobst T
    Endoscopy; 1995 Sep; 27(7):512-5. PubMed ID: 8565892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitigating conflicts of interest in chemical safety testing.
    Volz DC; Elliott KC
    Environ Sci Technol; 2012 Aug; 46(15):7937-8. PubMed ID: 22835037
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessing and managing risks arising from exposure to endocrine-active chemicals.
    Phillips KP; Foster WG; Leiss W; Sahni V; Karyakina N; Turner MC; Kacew S; Krewski D
    J Toxicol Environ Health B Crit Rev; 2008 Mar; 11(3-4):351-72. PubMed ID: 18368561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxic control.
    Nature; 2016 Jun; 534(7605):5-6. PubMed ID: 27251236
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.